Dizhe Pharmaceutical (688192.SH) issued an announcement, and the company's product Suvorazhe (generic name: suvoritinib) was awarded by the United States...
Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that the company's product Schwarzhe (generic name: suvetinib) was certified as a “breakthrough therapy” by the US Food and Drug Administration (“FDA”) for first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations. This is followed by advanced NSCLC (exon20ins) mutations in the EGFR exon20ins mutant First in the field to win both China and the US” “Breakthrough Therapy Accreditation” is another important milestone after the country's innovative drug. Currently, Schwarzer is the only drug that has been recognized as a breakthrough therapy by the FDA to treat EGFR exon20ins mutant nsCLC.